229 related articles for article (PubMed ID: 28225499)
1. Primary cutaneous diffuse large B cell lymphoma-other successfully treated by the combination of R-CHOP chemotherapy and surgery: A case report and review of literature.
Jia J; Li W; Zheng Y
Medicine (Baltimore); 2017 Feb; 96(8):e6161. PubMed ID: 28225499
[TBL] [Abstract][Full Text] [Related]
2. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
3. Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases.
Li X; Shen W; Cao J; Wang J; Chen F; Wang C; Zou S; Shen B; Zhao R; Li J; Shen Z
Ann Hematol; 2012 Nov; 91(11):1721-9. PubMed ID: 22733613
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
Ferrara F; Ravasio R
Clin Drug Investig; 2008; 28(1):55-65. PubMed ID: 18081361
[TBL] [Abstract][Full Text] [Related]
5. A case of primary adrenal diffuse large B-cell lymphoma achieving complete remission with rituximab-CHOP chemotherapy.
Kim KM; Yoon DH; Lee SG; Lim SN; Sug LJ; Huh J; Suh C
J Korean Med Sci; 2009 Jun; 24(3):525-8. PubMed ID: 19543522
[TBL] [Abstract][Full Text] [Related]
6. Secondary central nervous system involvement in 599 patients with diffuse large B-cell lymphoma: are there any changes in the rituximab era?
Deng L; Song Y; Zhu J; Zheng W; Wang X; Xie Y; Lin N; Tu M; Ping L; Ying Z; Liu W; Zhang C
Int J Hematol; 2013 Dec; 98(6):664-71. PubMed ID: 24234713
[TBL] [Abstract][Full Text] [Related]
7. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
[TBL] [Abstract][Full Text] [Related]
8. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
[TBL] [Abstract][Full Text] [Related]
9. Comparison of therapeutic outcomes between surgical resection followed by R-CHOP and R-CHOP alone for localized primary intestinal diffuse large B-cell lymphoma.
Lee HS; Park LC; Lee EM; Shin SH; Ye BJ; Oh SY; Song MK; Lee SM; Lee WS; Kang BW; Chang MH; Cho SG; Yahng SA; Yoon SS; Kwon JH; Kim YS
Am J Clin Oncol; 2014 Apr; 37(2):182-7. PubMed ID: 23211226
[TBL] [Abstract][Full Text] [Related]
10. Complete remission of primary cutaneous intravascular large B-cell lymphoma with R-CHOP followed by rituximab monotherapy.
Pantelaki I; Tigges C; Nußbaum T; Oellig F; Wieland U; Kreuter A
Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28508527
[No Abstract] [Full Text] [Related]
11. Primary diffuse large B-Cell lymphoma of the prostate presenting with urinary retention and dyschezia for which rituximab-combined CHOP therapy was effective-a case presentation.
Manabe M; Hayashi Y; Yoshii Y; Mukai S; Sakamoto E; Kanashima H; Nakao T; Hayama T; Fukushima H; Inoue T; Yamane T; Teshima H
Gan To Kagaku Ryoho; 2012 Nov; 39(11):1733-5. PubMed ID: 23152030
[TBL] [Abstract][Full Text] [Related]
12. A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma.
Hainsworth JD; Arrowsmith ER; McCleod M; Hsi ED; Hamid O; Shi P; Lin BK; Fayad LE
Leuk Lymphoma; 2016; 57(1):216-8. PubMed ID: 25956042
[No Abstract] [Full Text] [Related]
13. The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma.
Sohn BS; Kim SM; Yoon DH; Kim S; Lee DH; Kim JH; Lee SW; Huh J; Suh C
Ann Hematol; 2012 Nov; 91(11):1731-9. PubMed ID: 22752193
[TBL] [Abstract][Full Text] [Related]
14. Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy.
Hong J; Woo HS; Kim H; Ahn HK; Sym SJ; Park J; Ahn JY; Cho EK; Shin DB; Lee JH
Cancer Sci; 2014 Dec; 105(12):1569-75. PubMed ID: 25263825
[TBL] [Abstract][Full Text] [Related]
15. Primary ovarian lymphoma--a rare entity.
Afshan A; Sadaf N
J Pak Med Assoc; 2013 Apr; 63(4):519-20. PubMed ID: 23905454
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Feugier P; Van Hoof A; Sebban C; Solal-Celigny P; Bouabdallah R; Fermé C; Christian B; Lepage E; Tilly H; Morschhauser F; Gaulard P; Salles G; Bosly A; Gisselbrecht C; Reyes F; Coiffier B
J Clin Oncol; 2005 Jun; 23(18):4117-26. PubMed ID: 15867204
[TBL] [Abstract][Full Text] [Related]
17. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
[TBL] [Abstract][Full Text] [Related]
18. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group.
Seki R; Ohshima K; Nagafuji K; Fujisaki T; Uike N; Kawano F; Gondo H; Makino S; Eto T; Moriuchi Y; Taguchi F; Kamimura T; Tsuda H; Ogawa R; Shimoda K; Yamashita K; Suzuki K; Suzushima H; Tsukazaki K; Higuchi M; Utsunomiya A; Iwahashi M; Imamura Y; Tamura K; Suzumiya J; Yoshida M; Abe Y; Matsumoto T; Okamura T
Int J Hematol; 2010 Mar; 91(2):258-66. PubMed ID: 20066574
[TBL] [Abstract][Full Text] [Related]
19. Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.
Kraft RM; Ansell SM; Villasboas JC; Bennani NN; Wang Y; Habermann TM; Thanarajasingam G; Lester SC; Macon W; Inwards DJ; Porrata LF; Micallef IN; Witzig TE; Thompson CA; Johnston PB; Nowakowski GS; Lin Y; Paludo J
Hematol Oncol; 2021 Dec; 39(5):658-663. PubMed ID: 34453851
[TBL] [Abstract][Full Text] [Related]
20. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
